Regulatory
Why Patient Adherence is a Policy Issue
Patient non-adherence is costing the US healthcare system nearly $290 billion annually and accounts for approximately 13 percent of the total healthcare expenditures. From a government perspective, the need to rein in healthcare costs, long a political priority for some, is now a fiscal necessity. Joe Ganley outlines some macro trends in public policy that he says will impact adherence significantly ...Read more
Digital Pharma
Is Pinterest the Risk-Free Social Channel for Pharma?
Spoiler Alert: the answer is no, writes Peter Houston. Social media participation is never entirely without risk, but Pinterest presents and intriguing opportunity for Pharma to join the visual web ...Read more
Obamacare
Those Amazing ‘Gold Plated, Cadillac Care’ Drug Programs
Some 20% of Americans enjoy the benefits of a robust, corporate-funded drug benefit plan, but new taxes on so-called ‘Cadillac care’ plans arising from provisions in the Affordable Care Act could take some health insurance beneficiaries – and pharma – by surprise, writes Tom Norton, particularly when coverage decisions, and individual costs, get shifted onto patients ...Read more
Value
For What It’s Worth: Study Probes Evolving Value Schemes
A new study determines that collaboration across three fronts is needed to ensure that value is recognized and adapted over time, taking into account real-world evidence ...Read more
SciVigilance – Pharmacovigilance in a box
Effective safety and risk management is a result of a multi-tiered effort that ensures the safety of a product and mitigates the risks for pharmaceutical companies. While pharmacovigilance depends extensively on human sources for information input and processing of data, the growing volume of data and evolving regulations necessitates robust technology enabled process execution to manage the myriad of risks. Read More
Legal
Lanham Act: Peer Review on Trial
Scientific opinion has special protection under the First Amendment, but does that give pharma a free pass to BYOD – build your own dataset – publish a peer-reviewed article based on the data, and then promote it for competitive advantage? The 2nd US Circuit Court of Appeals weighs in ...Read more
Global
Whatever Happened to Outsourcing in Asia?
Last year, industry research pointed to China and India as the industry's top potential destinations for offshoring over the next five years, which put them ahead of traditional biomanufacturing hubs in the US and Western Europe. A new report, however, suggests that enthusiasm may have diminished ...Read more
|
